Unicycive Therapeutics, Inc. (UNCY)

Market Cap	37.19M
Revenue (ttm)	n/a
Net Income (ttm)	-31.41M
Shares Out	34.76M
EPS (ttm)	-1.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	243,117
Open	1.170
Previous Close	1.150
Day's Range	1.070 - 1.190
52-Week Range	0.470 - 1.823
Beta	2.65
Analysts	Strong Buy
Price Target	5.50 (+414.02%)
Earnings Date	May 14, 2024

About UNCY

Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 13, 2021
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: UNCY

Analyst Forecast

According to 5 analysts, the average rating for UNCY stock is "Strong Buy." The 12-month stock price forecast is $5.5, which is an increase of 414.02% from the latest price.

Price Target

$5.5

(414.02% upside)

Analyst Consensus: Strong Buy